S16) showed trends toward higher-magnitude CD8+ and CD4+ responses to both spike and nucleocapsid in COVID-19 convalescent participants compared to the controls, which was significant for the spike-specific CD4+ responses (P = 0.036), but no significant differences were observed between the baseline and 4-month follow-up scans. The gene discussed is CD8A; the disease is COVID-19.